ARTICLE | Company News
Anthra, Paladin deal
October 25, 1999 7:00 AM UTC
PLB received exclusive rights in Canada to Anthra’s Valstar valrubicin, a chemotherapeutic for intravesical therapy of refractory carcinoma in situ of the bladder. Anthra received a $1 million equity...